BIOL logo

BIOLASE, Inc. (BIOL)

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

BIOLASE, Inc. (BIOL) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 47/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.

Zuletzt analysiert: 17. März 2026
47/100 KI-Bewertung

BIOLASE, Inc. (BIOL) Gesundheitswesen & Pipeline-Uebersicht

CEOJohn R. Beaver
Mitarbeiter157
HauptsitzFoothill Ranch, US
IPO-Jahr1992

BIOLASE, Inc. focuses on dental laser systems, offering Waterlase and diode laser technologies for a range of dental procedures. With a global presence and a direct sales force, BIOLASE competes in the dental device market, emphasizing minimally invasive solutions for dentists and specialists.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 17. März 2026

Investmentthese

BIOLASE, Inc. operates in the dental laser market, a segment driven by the increasing demand for minimally invasive dental procedures. The company's innovative Waterlase and diode laser systems provide a competitive edge. Key value drivers include expanding the installed base of laser systems and increasing recurring revenue from consumables and accessories. Growth catalysts include ongoing advancements in laser technology and expanding the applications of dental lasers. The company's gross margin stands at 34.0%. Potential risks include competition from established dental equipment manufacturers and the need for continuous innovation to maintain market share. The company's market capitalization is $0.00B, and it has a negative P/E ratio.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • BIOLASE operates with 157 employees, indicating a relatively lean operational structure.
  • The company's gross margin is 34.0%, reflecting its ability to generate revenue above the cost of goods sold.
  • BIOLASE has a negative profit margin of -42.0%, signaling challenges in achieving overall profitability.
  • The company's beta is 0.68, suggesting lower volatility compared to the broader market.
  • BIOLASE does not currently offer a dividend, which is common for growth-oriented companies in the medical device sector.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Innovative laser technology for minimally invasive dental procedures.
  • Established presence in the dental laser market.
  • Direct sales force and distributor network.
  • Comprehensive product portfolio including laser systems and consumables.

Schwaechen

  • Negative profit margin indicating financial challenges.
  • Limited market capitalization.
  • Dependence on a niche market segment.
  • Intense competition from established dental equipment manufacturers.

Katalysatoren

  • Upcoming: Potential FDA approvals for new laser applications could expand market reach.
  • Ongoing: Increasing adoption of minimally invasive dental procedures drives demand for BIOLASE's products.
  • Ongoing: Strategic partnerships with dental clinics and universities can enhance market penetration.

Risiken

  • Potential: Competition from established dental equipment manufacturers could erode market share.
  • Potential: Economic downturn may impact dental spending and demand for BIOLASE's products.
  • Ongoing: Regulatory changes in the dental industry could affect product approvals and market access.

Wachstumschancen

  • Expanding the installed base of Waterlase and diode laser systems represents a significant growth opportunity for BIOLASE. By increasing the number of dental practitioners using its laser systems, the company can drive revenue growth and establish a stronger market presence. This expansion can be achieved through targeted marketing campaigns, strategic partnerships with dental clinics, and participation in industry conferences. The market for dental laser systems is projected to grow as more dentists adopt minimally invasive techniques, presenting a favorable environment for BIOLASE's growth.
  • Increasing recurring revenue from consumables and accessories is another key growth driver for BIOLASE. As the installed base of laser systems expands, the demand for consumable products such as flexible fibers, hand pieces, and teeth whitening gel kits will also increase. By offering high-quality consumables and accessories, BIOLASE can generate a steady stream of recurring revenue and enhance customer loyalty. This strategy aligns with the company's focus on providing comprehensive solutions for dental practitioners, fostering long-term relationships and driving sustainable growth.
  • Developing new applications for dental lasers represents a significant growth opportunity for BIOLASE. By expanding the range of procedures that can be performed using its laser systems, the company can attract new customers and increase the utilization of its existing products. This can be achieved through ongoing research and development efforts, clinical trials, and collaborations with dental professionals. The potential applications for dental lasers are vast, ranging from cosmetic dentistry to surgical procedures, offering ample opportunities for BIOLASE to innovate and expand its market reach.
  • Expanding into new geographic markets is a strategic growth opportunity for BIOLASE. By entering new regions, the company can diversify its revenue streams and reduce its reliance on existing markets. This expansion can be achieved through strategic partnerships with local distributors, participation in international dental conferences, and targeted marketing campaigns. The global market for dental laser systems is growing, presenting a favorable environment for BIOLASE to expand its international presence and capitalize on new opportunities.
  • Collaborating with dental schools and universities to integrate BIOLASE's laser systems into dental education programs can drive long-term growth. By training future dentists on its products, the company can create a pipeline of potential customers and establish a strong brand presence within the dental community. This can be achieved through partnerships with dental schools, offering training programs, and providing access to its laser systems for educational purposes. This initiative will help BIOLASE foster brand loyalty and drive future sales as these students enter professional practice.

Chancen

  • Expanding the installed base of laser systems.
  • Increasing recurring revenue from consumables and accessories.
  • Developing new applications for dental lasers.
  • Expanding into new geographic markets.

Risiken

  • Competition from established dental equipment manufacturers.
  • Technological advancements by competitors.
  • Regulatory changes affecting the dental industry.
  • Economic downturn impacting dental spending.

Wettbewerbsvorteile

  • Proprietary laser technology with patents.
  • Established brand recognition in the dental laser market.
  • Direct sales force and distributor network providing market access.
  • Focus on minimally invasive dental procedures.

Ueber BIOL

BIOLASE, Inc., established in 1984 and headquartered in Foothill Ranch, California, specializes in the development, manufacture, and marketing of laser systems for the dental industry. The company's core offerings include the Waterlase all-tissue dental laser systems, designed for cutting both soft and hard tissues, and diode soft-tissue laser systems used in soft tissue procedures, pain therapy, teeth whitening, and cosmetic applications. Additionally, BIOLASE offers the Epic Hygiene laser, which is used to manage non-surgical periodontitis and enhance clinical production. These laser systems enable dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a variety of minimally invasive dental procedures, ranging from cosmetic and restorative to complex surgical applications. BIOLASE also provides consumable products and accessories for its laser systems, including flexible fibers, hand pieces, and teeth whitening gel kits. The company distributes its products through a direct field sales force and a network of distributors, serving dental practitioners and their patients both in the United States and internationally. Formerly known as BIOLASE Technology, Inc., the company rebranded to BIOLASE, Inc. in 2012, marking a strategic shift in its corporate identity and market focus.

Was das Unternehmen tut

  • Develops and manufactures Waterlase all-tissue dental laser systems.
  • Offers diode soft-tissue laser systems for various dental procedures.
  • Provides Epic Hygiene laser for managing non-surgical periodontitis.
  • Sells consumable products and accessories for its laser systems.
  • Markets flexible fibers and hand pieces for dental lasers.
  • Offers teeth whitening gel kits.
  • Distributes products through a field sales force and distributor network.

Geschaeftsmodell

  • Sells dental laser systems to dental practitioners and specialists.
  • Generates revenue from consumable products and accessories.
  • Provides training and support services for its laser systems.

Branchenkontext

BIOLASE operates within the medical device industry, specifically focusing on dental laser systems. The dental device market is characterized by technological advancements and a growing demand for minimally invasive procedures. Competition includes established dental equipment manufacturers and specialized laser companies. The industry is driven by factors such as an aging population, increasing awareness of oral health, and advancements in dental technology. BIOLASE's focus on laser-based solutions positions it within a niche segment of this broader market.

Wichtige Kunden

  • Dentists
  • Periodontists
  • Endodontists
  • Oral Surgeons
  • Dental Hygienists
KI-Zuversicht: 71% Aktualisiert: 17. März 2026

Finanzdaten

Chart & Info

BIOLASE, Inc. (BIOL) Aktienkurs: Price data unavailable

Aktuelle Nachrichten

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer BIOL.

Kursziele

Wall-Street-Kurszielanalyse fuer BIOL.

MoonshotScore

47/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von BIOL auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Fuehrung: John R. Beaver

CEO

John R. Beaver serves as the CEO of BIOLASE, Inc. His professional background includes extensive experience in managing and leading technology-driven companies. He is responsible for overseeing the strategic direction, operational execution, and financial performance of the company. His leadership aims to drive innovation, expand market reach, and enhance shareholder value. Further details regarding his specific career history and educational background are not available.

Erfolgsbilanz: Under John R. Beaver's leadership, BIOLASE has focused on expanding its product portfolio and market presence in the dental laser industry. Key initiatives include enhancing the company's sales and marketing efforts, driving innovation in laser technology, and strengthening relationships with dental professionals. Specific achievements and milestones under his tenure are not available.

BIOL Healthcare Aktien-FAQ

What are the key factors to evaluate for BIOL?

BIOLASE, Inc. (BIOL) currently holds an AI score of 47/100, indicating low score. Key strength: Innovative laser technology for minimally invasive dental procedures.. Primary risk to monitor: Potential: Competition from established dental equipment manufacturers could erode market share.. This is not financial advice.

How frequently does BIOL data refresh on this page?

BIOL prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven BIOL's recent stock price performance?

Recent price movement in BIOLASE, Inc. (BIOL) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative laser technology for minimally invasive dental procedures.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider BIOL overvalued or undervalued right now?

Determining whether BIOLASE, Inc. (BIOL) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying BIOL?

Before investing in BIOLASE, Inc. (BIOL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding BIOL to a portfolio?

Potential reasons to consider BIOLASE, Inc. (BIOL) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Innovative laser technology for minimally invasive dental procedures.. Additionally: Established presence in the dental laser market.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of BIOL?

Yes, most major brokerages offer fractional shares of BIOLASE, Inc. (BIOL) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track BIOL's earnings and financial reports?

BIOLASE, Inc. (BIOL) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for BIOL earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • Financial data is based on the most recent available information.
  • AI analysis is pending, and analyst opinions may vary.
  • Market conditions and competitive landscape are subject to change.
Datenquellen

Popular Stocks